Sientra (NASDAQ: SIEN) and OraSure Technologies (NASDAQ:OSUR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, dividends, earnings and risk.

Volatility & Risk

Sientra has a beta of -1.47, indicating that its share price is 247% less volatile than the S&P 500. Comparatively, OraSure Technologies has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500.

Insider and Institutional Ownership

76.6% of Sientra shares are held by institutional investors. Comparatively, 94.4% of OraSure Technologies shares are held by institutional investors. 28.1% of Sientra shares are held by company insiders. Comparatively, 6.4% of OraSure Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Sientra and OraSure Technologies’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Sientra $20.73 million 14.00 -$40.16 million ($2.85) -5.25
OraSure Technologies $128.20 million 8.73 $19.72 million $0.52 35.50

OraSure Technologies has higher revenue and earnings than Sientra. Sientra is trading at a lower price-to-earnings ratio than OraSure Technologies, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Sientra and OraSure Technologies, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sientra 0 1 4 0 2.80
OraSure Technologies 0 1 4 0 2.80

Sientra currently has a consensus target price of $13.75, suggesting a potential downside of 8.09%. OraSure Technologies has a consensus target price of $17.25, suggesting a potential downside of 6.55%. Given OraSure Technologies’ higher probable upside, analysts clearly believe OraSure Technologies is more favorable than Sientra.

Profitability

This table compares Sientra and OraSure Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sientra -169.77% -68.82% -43.13%
OraSure Technologies 20.48% 14.12% 12.57%

Summary

OraSure Technologies beats Sientra on 9 of the 11 factors compared between the two stocks.

About Sientra

Sientra, Inc. is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons. Its breast implants are primarily used in elective procedures, which are generally performed on a cash-pay basis. TRUE Texture provides texturing on the implant shell that is designed to reduce the incidence of malposition, rotation and capsular contracture. The Company also offers breast tissue expanders and a range of other aesthetic and specialty products. The Company offers a range of HSC+ breast implants, including anatomically shaped textured, round textured and round smooth. The Company also offers miraDry system, the device to reduce underarm sweat, odor and permanently reduce hair of all colors.

About OraSure Technologies

OraSure Technologies, Inc. (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The Company operates in two segments: OSUR and DNAG. OSUR consists of the development, manufacture and sale of diagnostic products, specimen collection devices, and medical devices. DNAG or molecular collection systems business consists primarily of the development, manufacture and sale of oral fluid collection devices that are used to collect, stabilize, and store samples of genetic material for molecular testing. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. It sells over-the-counter (OTC) cryosurgical products to consumers in North America, Europe, Central and South America, and Australia.

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.